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Abstract
Background: Blockade of the renin angiotensin system (RAS) via angiotensin I converting enzyme (ACE) inhibition 
reduces growth of colorectal cancer (CRC) liver metastases in a mouse model. In this work we defined the expression of 
the various components of the RAS in both tumor and liver during the progression of this disease.
Methods: Immunohistochemistry and quantitative RT-PCR was used to examine RAS expression in a mouse CRC liver 
metastases model. CRC metastases and liver tissue was assessed separately at key stages of CRC liver metastases 
development in untreated (control) mice and in mice treated with the ACE inhibitor captopril (750 mg/kg/day). Non-
tumor induced (sham) mice indicated the effect of tumors on normal liver RAS. The statistical significance of multiple 
comparisons was determined using one-way analysis of variance followed by Bonferroni adjustment with SAS/STAT 
software.
Results: Reduced volume of CRC liver metastases with captopril treatment was evident. Local RAS of CRC metastases 
differed from the surrounding liver, with lower angiotensin II type 1 receptor (AT1R) expression but increased ANG-(1-7) 
receptor (MasR) compared to the liver. The AT1R localised to cancer and stromal infiltrating cells, while other RAS 
receptors were detected in cancer cells only. Tumor induction led to an initial increase in AT1R and ACE expression 
while captopril treatment significantly increased ACE expression in the final stages of tumor growth. Conversely, 
captopril treatment decreased expression of AT1R and angiotensinogen.
Conclusions: These results demonstrate significant changes in RAS expression in the tumor-bearing captopril treated 
liver and in CRC metastases. The data suggests the existence of a tumor-specific RAS that can be independently 
targeted by RAS blockade.
Background
Colorectal cancer (CRC) is a leading cause of cancer
death worldwide, with approximately 940 000 new cases
and 500 000 deaths reported annually [1]. Mortality from
CRC is primarily due to metastasis to the liver, account-
ing for over 70% of deaths [2]. Surgical resection provides
the best chance of cure. However , only 20% to 25% of
patients are eligible for surgery, with recurrence rates
approaching 40% to 70% [3,4]. Palliative systemic chemo-
therapy is the preferred option for the majority of these
patients.
Recent studies suggest that therapies targeting para-
crine hormone systems that promote tumor development
may provide an alternative or additional treatment strat-
egy in these patients. There is strong evidence that long
term blockade of the renin angiotensin system (RAS) in
hypertensive patients is associated with a decreased inci-
dence of several human cancers [5]. Evidence also sug-
gests that blockade of the RAS in experimental animal
models of CRC liver metastases is associated with tumor
growth inhibition [6-9]. The angiotensin I converting
enzyme (ACE) is a key enzyme in the RAS, cleaving the
biologically inactive angiotensin (ANG) I precursor to
ANG II, the key effector peptide of the RAS. ACE inhibi-
tion is associated with a reduction in tumor growth for
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several malignancies including breast, prostate, lung, and
colon cancer [5,10-12].
In the liver, the local RAS is up-regulated in response to
tissue injury and hypoxia [13,14]. However, its expression
during the development of CRC liver metastases has not
been examined. ANG II stimulates the expression of sev-
eral growth and pro-angiogenic factors including vascu-
lar endothelial growth factor (VEGF) [15,16]. The pro-
angiogenic effects of ANG II are mediated by the ANG II
type 1 receptor (AT1R), which is overexpressed in several
human cancers [7-19].
Recent studies demonstrate that while ANG II/AT1R
signalling has proliferative and angiogenic effects, coun-
ter-regulatory effects are mediated by other RAS compo-
nents. For example, activation of the AT2R, which is
expressed in preference to AT1R in primary CRC, inhib-
its angiogenesis and cellular proliferation [20,21]. In addi-
tion, a homologue of ACE, ACE2, was recently described
and its expression is up-regulated in liver injury [13,22-
24]. This enzyme generates the peptide ANG-(1-7)
directly from ANG II and indirectly from ANG I [23].
ANG-(1-7) acts through the MasR (mitochondrial
assembly receptor) and appears to antagonize some ANG
II-induced effects, including angiogenesis and cellular
proliferation [25-27]. Although ANG-(1-7) decreases
proliferation of several cell types, including human lung
cancer cells in vitro [28], it has also been associated with
increased cellular proliferation [29,30].
Several components of the RAS are expressed in pri-
mary CRC and we have shown previously that blockade
of the RAS decreased tumor growth in a mouse model of
CRC liver metastases [8,19]. However, the ontogeny of
RAS expression during CRC liver metastases progression
has not been described, nor have the effects of captopril
treatment on RAS expression in tumors been docu-
mented. This study aimed to establish an expression pro-
file of the RAS in both captopril treated and untreated
early, mid, and late stages of CRC liver metastases.
Methods
Animals
Male inbred 6-8 week old CBA mice were obtained from
Adelaide University Animal Facility, Australia. Experi-
ments were performed according to the Austin Health
Animal Ethics Committee guidelines.
Mouse model of colorectal liver metastases
A mouse model of CRC liver metastases was used as
described previously [31]. A dimethyl-hydrazine-induced
primary colon carcinoma was maintained by in vivo serial
passage in the flanks of male CBA mice. T umors were
removed from passage mice and used to make a tumor
cell suspension (1 × 106 cells/ml in Ringers solution/0.1%
glucose). For tumor-induction, mice were anaesthetized
with an intraperitoneal injection (0.1 ml/10 mg body
weight) of ketamine/xylazine. The spleen was exterior-
ized through a subcostal incision. Tumor cell suspension
(0.05 ml) was slowly injected into the spleen using a 25-
gauge needle over a period of 1 minute. The needle was
retracted and even pressure was applied to the spleen for
2 minutes. A haemostatic clip sealed the splenic vessels
and a splenectomy was performed. The skin was sutured
and the mouse recovered on a heated pad. Sham mice
had a 0.05 ml injection of Ringers/0.1% glucose solution
and a splenectomy.
This model has been characterized previously and
results in metastases exclusively confined to the liver [31].
Angiogenesis is established by day 10, followed by expo-
nential growth of tumors between days 10-16, and a pla-
teau phase from day 19-22.
Sample collection
Liver samples from 3-5 animals per time point and treat-
ment were collected at 5, 10, 16 and 21 days after CRC
liver metastases induction. However, because of the small
size of tumors in the early stages (days 5 and 10), analysis
of CRC metastases was restricted to days 16 and 21. All
effort was made to completely separate tumor from adja-
cent liver; however, contamination from micro metasta-
ses cannot be excluded from samples of the tumor-
bearing liver.
Captopril treatment
Captopril (D-3-mercapto-2-methylpropanoyl-L-proline,
Sigma-Aldrich, Sydney, NSW, Australia) was made fresh
in PBS. The dosing regime was as described previously
[8]. Briefly, captopril was administered daily to mice via
intraperitoneal injection (750 mg/kg; at a volume of 0.3
ml). Dosing began on the day of CRC liver metastases
induction and continued daily until the experimental
endpoint. Control mice received an equivalent volume of
PBS.
RNA extraction and cDNA synthesis
Liver and CRC metastases tissues were homogenized in 1
ml of Trizol (Invitrogen) to obtain total RNA. RNA was
DNase treated (Ambion, DNA-free™) to remove contami-
nating genomic DNA. RNA concentration and purity
were determined using a spectrophotometer. Approxi-
mately 1 μg of total RNA, 100 ng of random hexamers
(Invitrogen), 2 μl deoxyribonucleotide triphosphate (10
mM dNTP), and 2000 U of reverse transcriptase were
used in a cDNA synthesis reaction.
Quantitative RT-PCR (qRT-PCR) analysis
An aliquot of cDNA (between 5 and 100 ng of cDNA
according to primer efficiency and the anticipated level of
expression for each gene) was used in a qRT-PCR (ABI
Prism 7700 Sequence Detector). To confirm the absenceNeo et al. BMC Cancer 2010, 10:134
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of contaminating genomic DNA, RT-minus and no tem-
plate controls were performed. Probes and primers for
mouse tissue were designed using Primer Express, Ver 1.0
(PE Applied Biosystems, Foster City, CA) and ordered
from Geneworks (Table 1). Each cDNA sample was ana-
lyzed in duplicate and assessed using the comparative CT
method. The qRT-PCR protocol began with a 50°C incu-
bation for 2 minutes, followed by 95°C for 10 minutes,
and 45 cycles at 95°C for 15 seconds and 60°C for 1 min-
ute. 18S ribosomal RNA served as the internal control.
Values from non-treated and treated liver and liver
metastases were normalized against sham livers, which
were given a value of 1.
Immunohistochemistry
To measure RAS proteins, samples were collected in 4%
paraformaldehyde and fixed for 48 hours before embed-
ding in paraffin. Sections were cut at 4 μm and mounted
on SuperFrost Plus slides (Menzel-Glaser). Sections were
dewaxed in two 10 minutes histolene solvent baths and
rehydrated by serial progression through three 100%
EtOH baths. Endogenous peroxidase activity was blocked
with 3% hydrogen peroxide in TBST for 5 minutes. For
the ACE H-170 antibody (rabbit polyclonal, Santa Cruz,
cat# sc-20791) and the AT2R antibody (rabbit polyclonal,
Santa Cruz, cat# sc-9040), an antigen retrieval step in cit-
rate buffer (10 mM, pH 6) for 15 and 10 minutes, respec-
tively, at low microwave power was required. AT1R and
MasR immunostaining did not require antigen retrieval.
The ACE H-170 antibody was applied at 0.001 g/L, the
AT1R antibody (rabbit polyclonal, Santa Cruz, cat# sc-
1173) at 1 μg/mL, the AT2R antibody at 2.5 μg.mL, and
the MasR antibody (rabbit polyconal, Lifespan Biosci-
ences, cat# LS-A1528) at 10 μg/mL. Control sections
were incubated in diluent or appropriate IgG negative
control. Slides were incubated at 37°C for 2 hours (ACE,
AT1R and the MasR antibody) or for an hour (AT2R anti-
body) followed by an overnight 4°C incubation. Slides
were then incubated for 1 hour at 37°C with an anti-rab-
bit horseradish peroxidase secondary antibody (Dako,
cat# 4011). The final detection step was carried out using
3,3'-diaminobenzidine (DAB, Dako, cat# 4011) as the
chromogen. Sections were counterstained with Mayer's
hematoxylin for 3 minutes and cover slipped.
ACE positive cell counts
The Nikon Coolscope digital microscope and Image Pro
P l u s  i m a g e  a n a l y s i s  s y s t e m  w e r e  u s e d  t o  q u a n t i f y  t h e
number of cells in the tumor stroma and used each
nucleus that was associated with surrounding ACE posi-
tive staining to distinguish individual cells in treated and
un-treated tumors. Positively staining cells were counted
per high-powered field (20 × magnification) and mea-
sured relative to tumor area. For each section, between 7
and 40 images were captured (depending on the number/
size of tumors). Cell counts were averaged to give a single
value for each section/individual. Between 4 and 6 indi-
viduals were assessed at each stage. Cell counts were per-
formed on day 16 and 21 tumors, but not in the adjacent
liver as ACE positive staining localized to non-sinusoidal
endothelial cells in all treatments and conditions and dif-
ferences in staining intensity could not be assessed with
the antibody used.
Table 1: Primer and probe sequences for qRT-PCR listed from the 5' to 3' direction.
Gene Primer Size (bp) Probe Size
(bp)
Mas R Forward TGTGGGCACTTTCGTGCTT
Reverse 
AATGACTCTCTTCTCCGCTGTCA
19
23
CACCATGGAGTATGTC
ATGT
20
ACE Forward 
CAGAATCTACTCCACTGGCAAGGT
Reverse 
TCGTGAGGAAGCCAGGATGT
24
20
CAACAAGACTGCCACC
TGCTGGTCC
25
ACE2 Forward TGCCCATTTGCTTGGTGAT
Reverse 
AAAGGGAACAGTCAAAGGGTACAG
19
24
TTTGTCCAAAATCTAC
CCCACA
22
AT1R Forward 
GGGCAGTTTATACCGCTATGGA
Reverse TGGCCGAAGCGATCTTACAT
22
20
TACCAGTGGCCCTTCG
GCAATCA
23
AT2R Forward 
ATTACCTGCATGAGTGTCGATAGG
Reverse AGATGCTTGCCAGGGATTCC
24
20
ACCAATCGGTCATCTA
CCCTTTTCTGTCTC
30
Angioten-siongen Forward 
CTGCTCCAGGCTTTCGTCTAA
Reverse 
AGAACTGGGTCAGTGGATAAATCC
21
24
CCCTGCCCTCTTCCCA
CGCTCTC
23Neo et al. BMC Cancer 2010, 10:134
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Statistical analyses
The statistical significance of multiple comparisons was
determined using one-way analysis of variance followed
by Bonferroni adjustment with SAS/STAT software.
Quantitative data are presented as means ± s.e.m.. A P-
value less than 0.05 was defined as significant.
Results
Captopril inhibits CRC liver metastases
We previously described in detail the inhibitory effect of
pharmacological blockade of the RAS on CRC liver
metastases. We found that captopril administered daily at
a dose of 750 mg/kg dramatically decreased the number
and volume of tumors in a mouse model of CRC liver
metastases [8]. In the present study, we again adminis-
tered captopril using the same dosing regimen and ani-
mal model. Our present results confirm the previously
documented inhibitory effect of captopril on CRC liver
metastases (an example from day 21 is shown; Figure 1).
RAS expression in the liver and colorectal metastases
While the liver adjacent to CRC metastases was assessed
at days 5, 10, 16 and 21 by qRT-PCR, due to the small
tumor size at days 5 and 10, CRC metastases samples
were assessed only at days 16 and 21. Both CRC metasta-
ses and liver samples have been normalized against the
same sham livers at each time point. Statistical signifi-
cance for all comparisons is presented in Table 2, while
Figure 2 indicates significant differences between control
and treatment groups only.
Key components of the RAS, namely angiotensinogen,
ACE, ACE2, AT1R, AT2R, and the MasR were expressed
in the sham liver, tumor-induced liver, and in CRC liver
metastases (tumors) at all stages examined. Standard
deviations between replicate samples of the same cDNA
were less than 1 cycle, demonstrating the accuracy of the
qRT-PCR analyses performed. Variation between liver
samples between individuals may reflect contamination
from micrometastses or standard biological variation,
while deviations in CRC metastases samples likely reflect
the heterogeneous nature of these tumors.
Angiotensinogen expression is lower in CRC liver 
metastases and is reduced in the liver surrounding tumors 
following captopril treatment
Angiotensinogen mRNA expression in the liver sur-
rounding CRC metastases was not significantly different
from sham, indicating no effect of tumor-induction on
the expression of this gene. Angiotensinogen expression
in CRC metastases was unchanged by captopril treat-
ment, with no significant difference between control and
captopril treated CRC metastases at either day 16 or day
21. However, in the liver surrounding CRC metastases
treatment with captopril resulted in significantly lower
angiotensinogen mRNA expression at almost all time
points compared to both the sham and control tumor-
induced liver (P ≤ 0.0160) (Figure 2 and Table 2).
ACE and ACE2 expression in CRC liver metastases
A significant increase in ACE mRNA expression was
observed at day 5 in the tumor-bearing liver compared to
sham livers (P = 0.0412), indicating an effect of tumor
induction. However, the highest ACE expression levels
were observed in CRC metastases. ACE mRNA expres-
sion was higher in CRC metastases compared to the sur-
rounding liver at day 16 (P = 0.0007) and was increased
markedly at day 21 by captopril treatment; captopril
treated CRC metastases had significantly higher ACE
expression compared control CRC metastases (P  =
0.0001) (Figure 2) as well as to the surrounding liver (P =
0.0001).
Immunohistochemical staining for ACE localized this
protein to the stromal desmoplasia surrounding angio-
genic vessels in CRC metastases (Figure 3). In the normal
liver adjacent to CRC metastases, ACE localized to the
hepatic endothelial cells of liver veins and some sinusoi-
dal endothelial cells in both sham operated animals and
in tumor-bearing control and captopril treated animals.
Because no obvious difference in the number of ACE-
positive cells or in the localization of positively-stained
cells were observed in the liver tissue, cell counts were
not performed on the liver adjacent to CRC metastases.
However, marked differences in the number of positively
stained cells were observed in the stromal infiltrations
Figure 1 An example of CRC liver metastases inhibition by capto-
pril treatment. Captopril treated livers (e.g. A, dorsal; B, ventral) had 
noticeably fewer metastases than the corresponding tumor-bearing 
controls (e.g. C, dorsal; D, ventral). Control and captopril images are to 
the same scale. These results confirm our previous study which de-
scribed in detail the inhibitory effects of captopril on CRC liver metas-
tases [8].
A – captopril B – captopril
C – control D - controlNeo et al. BMC Cancer 2010, 10:134
http://www.biomedcentral.com/1471-2407/10/134
Page 5 of 11
within CRC metastases. At day 16 control tumors had
significantly more ACE-positive cells compared to capto-
pril treated CRC metastases, but ACE expression reverts
back to the level seen in untreated tumors at day 21 (Fig-
ure 4). Thus, the ACE-positive cell counts reflected
mRNA ACE expression in CRC metastases (Figure 2
and 4).
In contrast to ACE, ACE2 mRNA expression was lower
in tumors compared to the surrounding liver at day 21 in
control animals (P = 0.0011) (Table 2).
Classical and alternative RAS receptors are differentially 
expressed in CRC liver metastases
AT1R expression was elevated by tumor induction at day
5 (P = 0.0030) (Table 2). AT1R expression in the liver was
reduced by captopril treatment at days 5 (P = 0.0001) and
16 (P = 0.0003) (Figure 2). While in control animals CRC
metastases had significantly lower expression than the
surrounding liver (P = 0.019 day 16 and P = 0.0003 day
21), there was no difference between AT1R expression in
CRC metastases and liver of captopril treated animals.
Indeed, AT1R expression in the liver of captopril treated
animals was significantly less than the expression
detected in the livers of control animals (Table 2). In con-
trast to the AT1R, AT2R and MasR expression was higher
in CRC metastases compared to the surrounding liver,
reaching significance for the MasR (P ≤ 0.0046) (Table 2).
At day 16 MasR mRNA expression also increased in
tumors with captopril treatment (P = 0.0299) compared
to control CRC metastases (Figure 2).
Immunohistochemistry for the AT1R showed localiza-
tion to the stromal intrusions of CRC metastases in addi-
tion to cells lining the liver sinusoids (Figure 5). Staining
on tumors cells was observed only at the periphery and
was notably less intense than staining of the infiltrating
stromal cells. Given their location surrounding CRC
metastases and in the liver sinusoids it is likely that at
least some of these AT1R-positive cells are tumor-associ-
ated macrophages (liver Kupffer cells). Consistent with
our findings of AT1R mRNA expression, the number of
these AT1R-positive cells appeared lower in captopril
treated animals (see representative immunohistochemi-
cal images). While the AT1R localized to cells within the
surrounding liver, with comparatively light staining on
CRC metastases cells, only CRC metastases cells were
found to stain positively for the AT2R and the MasR.
These results support the finding that the mRNAs for
both these alternative receptors was notably higher in
CRC metastases than corresponding liver. The AT2R
localized to cells near the proliferating rim (tumor-liver
boundary), but, in contrast to the AT1R, did not extend
to this edge. The MasR localized to cell in and around
necrotic regions. The number of MasR-positive cells in
control CRC metastases at day 16 and day 21 was notice-
ably higher and more consistent than captopril treated
CRC metastases. Again these results support our mRNA
analysis of this receptor.
Discussion
RAS expression has been described in various cancer
cells and tissues and there is strong evidence that ACE
inhibition can inhibit tumor growth [7,9,11,32-37]. In our
previous study, we found that the administration of the
ACE inhibitor captopril caused a marked reduction in the
volume of CRC liver metastases and this was confirmed
in the present study which also demonstrated a local RAS
in CRC liver metastases that is distinct from the hepatic
RAS [8].
The RAS of colorectal cancer liver metastases is distinct 
from the liver RAS
ACE, AT1R, MasR, and angiotensinogen were differen-
tially expressed in control CRC liver metastases com-
Figure 2 Quantification of RAS mRNA expression by RT-PCR in 
sham livers, captopril-treated and control CRC liver metastases 
(tumors), and captopril-treated and control tumor-bearing liver 
(i.e. the liver surrounding tumors). Data for tumors is only presented 
at days 16 and 21 after induction as the small size of tumors was pro-
hibitive for accurate analysis at earlier stages. Sham livers were stan-
dardized to 1 and other values normalized against sham for each time 
point. Significance between captopril treated and control animals is 
shown by connecting dotted vertical lines. The significance of other 
comparisons is presented in Table 2. Only ACE2 was not significantly al-
tered either in CRC metastases or in the liver by captopril treatment.
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Table 2: Bonferroni adjusted t-tests for comparisons between RAS gene expression in tumors, tumor-induced liver, and 
sham livers either with or without captopril treatment.
Gene Comparison Day 5 Day 10 Day 16 Day 21
ACE Tumor control cf. 
sham
0.0003 0.3693
Tumor control cf. 
tumor captopril
0.0033 0.0001
Tumor control cf. 
liver control
0.0007 0.3508
Liver control cf. 
sham
0.0412 0.5001 0.4026 0.9496
Liver control cf. 
liver captopril
0.0005 0.2495 0.2839 0.6212
Liver captopril cf. 
sham
0.1202 0.5906 0.9216 0.6110
Tumor captopril 
cf. sham
0.1482 0.0001
Tumor captopril 
cf liver captopril
0.0796 0.0001
ACE2 Tumor control cf. 
sham
0.2276 0.0531
Tumor control cf. 
tumor captopril
0.2609 0.8660
Tumor control cf. 
liver control
0.9828 0.0011
Liver control cf. 
sham
0.9305 0.4077 0.6531 0.2105
Liver control cf. 
liver captopril
0.3797 0.2270 0.0598 0.3130
Liver captopril cf. 
sham
0.4554 0.6545 0.2146 0.8171
Tumor captopril 
cf. sham
0.0294 0.0838
Tumor captopril 
cf liver captopril
0.2259 0.0514
Ang Tumor control cf. 
sham
0.0119 0.3345
Tumor control cf. 
tumor captopril
0.7069 0.8632
Tumor control cf. 
liver control
0.0134 0.0024
Liver control cf. 
sham
0.0923 0.6725 0.6830 0.0530
Liver control cf. 
liver captopril
0.0004 0.0120 0.0108 0.0090
Liver captopril cf. 
sham
0.0160 0.0052 0.0098 0.5520
Tumor captopril 
cf. sham
0.0043 0.2801
Tumor captopril 
cf liver captopril
0.7858 0.5997Neo et al. BMC Cancer 2010, 10:134
http://www.biomedcentral.com/1471-2407/10/134
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AT1R Tumor control cf. 
sham
0.1071 0.0223
Tumor control cf. 
tumor captopril
0.4844 0.6327
Tumor control cf. 
liver control
0.0019 0.0003
Liver control cf. 
sham
0.0030 0.8065 0.1292 0.6180
Liver control cf. 
liver captopril
0.0001 0.1617 0.0003 0.2222
Liver captopril cf. 
sham
0.0787 0.2352 0.0360 0.5013
Tumor captopril 
cf. sham
0.0261 0.0677
Tumor captopril 
cf liver captopril
0.8570 0.2443
AT2R Tumor control cf. 
sham
0.7637 0.2765
Tumor control cf. 
tumor captopril
0.4973 0.9972
Tumor control cf. 
liver control
0.6145 0.0870
Liver control cf. 
sham
0.4505 0.2186 0.4791 0.8018
Liver control cf. 
liver captopril
0.4651 0.6104 0.0434 0.1241
Liver captopril cf. 
sham
0.9716 0.4497 0.2960 0.2765
Tumor captopril 
cf. sham
0.8127 0.0086
Tumor captopril 
cf liver captopril
0.2897 0.0749
MasR Tumor control cf. 
sham
0.0090 0.0033
Tumor control cf. 
tumor captopril
0.0299 0.3405
Tumor control cf. 
liver control
0.0036 0.0046
Liver control cf. 
sham
0.4294 0.2097 0.9185 0.6467
Liver control cf. 
liver captopril
0.2900 0.1486 0.8491 0.3546
Liver captopril cf. 
sham
0.0902 0.7769 0.9501 0.2062
Tumor captopril 
cf. sham
0.3995 0.0339
Tumor captopril 
cf liver captopril
0.2990 0.3248
Tumor comparisons have only been made for days 16 and 21 due to the difficult in obtaining sufficient samples at earlier stages (days 5 and 
10). Comparisons between liver tissues, however, have been made at all stages (Days 5, 10, 16 and 21 post-tumor induction). Values were 
considered significant for P < 0.05 (highlighted in bold).
Table 2: Bonferroni adjusted t-tests for comparisons between RAS gene expression in tumors, tumor-induced liver, and 
sham livers either with or without captopril treatment. (Continued)Neo et al. BMC Cancer 2010, 10:134
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pared to the naïve (non-tumor bearing) and the tumor-
bearing liver. In particular, CRC metastases were charac-
terised by high ACE and MasR expression, but low AT1R
and angiotensinogen mRNA levels compared to the liver.
These results indicate a distinct CRC cell-associated
RAS.
These cancer cells are derived from transformed epi-
thelial cells of the colon and the difference in RAS expres-
sion of these cells compared to the tumor-bearing and
naïve liver most likely represents a combination of differ-
ences due to transformation and tissue origin (colon ver-
sus liver). Hepatocytes are the major source of circulating
angiotensinogen and so it is perhaps not surprising that
CRC metastases have lower angiotensinogen levels [38].
These results also imply that much of the ANG II avail-
able to drive growth of CRC liver metastases is derived
from local host production of angiotensinogen, which is
then converted to ANG II via high ACE expression in
tumors. The high levels of tumor-derived ACE described
here support reports of an up-regulation of ACE mRNA
in primary CRCs compared to corresponding nonlesional
tissues [39]. However, our immunohistochemical analysis
suggests that at least some of the expression of ACE in
C R C  m e t a s t a s e s  i s  d e r i v e d  f r o m  i n f i l t r a t i n g  c e l l s.  I t  i s
known that infiltrating macrophages, which typically
associate with stromal intrusions, express ACE [40].
MasR expression was also markedly higher in CRC
metastases compared to the surrounding liver. The
MasR, as well as binding ANG-(1-7), was originally
described as a protoncogene based on its ability to trans-
form NIH 3T3 cells and its up-regulation in tumors may
represent a normal oncogenic pathway for CRC develop-
ment [41]. However, transgenic mice overexpressing
ANG-(1-7) do not have increased tumor formation and
MasR overexpression in the retina leads to increased cell
death without tumorgenicity suggesting that the MasR
itself is not oncogenic [42]. Importantly, increased MasR
expression may provide a target for initiating anti-tumor
responses since MasR activation by ANG-(1-7) mediates
a number of potentially anti-angiogenic and anti-prolifer-
ative effects. Indeed, ANG-(1-7) has been found to
reduce serum-stimulated growth in human lung cancer
cell lines [28].
AT1R protein is commonly expressed in several cancers
such as the bladder, pancreatic, ovarian and renal cancer
pulmonary metastasis [7-19]. However, in our study we
found that AT1R expression was lower in CRC metasta-
ses compared to the surrounding liver. AT1R protein
Figure 3 Immunohistochemical staining against ACE in the sham 
(B), control and captopril-treated animals at day 16 (C) and 21 (D). 
No staining was evident in the negative control (A). The sinusoidal, por-
tal vein, and central vein endothelium stained positively for ACE in the 
sham liver (B), and two images at higher magnification on the right). At 
day 16, there appeared to be more positive staining in control tumors 
compared to treated tumors (C). In contrast, at day 21 more cells 
stained positively for ACE when treated with captopril than when un-
treated (D).
Figure 4 ACE-positive cell counts in captopril treated and un-
treated tumors at days 16 and 21 after tumor-induction. Because 
all vascular endothelial cells stained in the liver regardless of treatment 
with captopril, cell counts for the corresponding normal liver were not 
performed. Changes in the number of ACE positive cells in response to 
captopril treatment was similar to ACE mRNA (see Figure 2), with great-
er numbers and mRNA expression in untreated CRC metastases at day 
16, but an increase in mRNA expression and number of ACE-positive 
cells by day 21 in treated CRC metastases.
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localized mainly to the stromal intrusions in liver metas-
tases with only light staining in the cancer cells them-
selves and confined to those cells at the proliferating
border of tumors. Given their location within the tumor
desmoplasia and liver sinusoids many of these AT1R-pos-
itive cells are likely to be Kupffer cells, resident liver mac-
rophages. Macrophages may contribute to tumor growth
by producing growth factors that enhance angiogenesis.
These infiltrating AT1R-positive cells may have a role in
mediating the effects of RAS blockade on tumor growth.
The results presented here support the hypothesis that
malignancies maintain a local RAS that reflects the tissue
in which the primary tumor developed. However, our
results do not preclude interactions between tumor and
host RASs and it is likely that both have paracrine effects
on the other.
Captopril treatment alters expression of the RAS in tumors
The significant reduction in ACE expression at day 16 fol-
lowing captopril treatment suggests that in addition to
the inhibition of ACE activity, captopril also reduces ACE
levels, presumably leading to an even greater inhibition of
ANG II production. The timing of this reduction in ACE
expression is of interest as it occurs during the critical
exponential growth phase (day 10 to 19). However, in the
late plateau stages (day 21 onwards) of CRC metastases
growth, captopril treatment was associated with a rever-
sion of ACE expression back to the levels seen in
u n t r e a t ed  t u m o r s  a t  d a y  2 1 .  I n  o u r  p r evi o u s  s t u d y  w e
stopped captopril treatment at day 21 and found survival
was not significantly improved in treated animals com-
pared to controls [8]. Our current results suggest a possi-
ble explanation for this, as the increased expression of
ACE mRNA (and protein) at this time would require
additional, or at least continued, captopril treatment to
ensure sustained inhibition of ACE activity.
Captopril altered the liver RAS
It is likely that much of the ANG II postulated to drive
growth of CRC metastases in the liver is derived from
angiotensinogen expressed by the liver parenchyma. We
also show that under captopril treatment angiotensino-
gen expression in the host liver was significantly reduced.
Thus, in the captopril treated liver, the production of
ANG II would be severely compromised by the inhibition
of its conversion from ANG I, the preferential production
of ANG-(1-7), and the reduction of angiotensinogen
expression, all of which would contribute to the reduced
availability of ANG II to support tumor growth [43,44].
Conclusions
In conclusion, the present study provides evidence of a
complete local RAS in both the normal and tumor-bear-
ing mouse liver. We show a marked up-regulation of ACE
during CRC metastases development, which would pre-
sumably favor CRC metastases growth by increasing pro-
duction of ANG II. Captopril treatment reduced CRC
metastases ACE expression during the period of rapid
growth, but ACE expression increased at late stages (day
21). This increase in ACE expression would need to be
taken into consideration if targeting ACE in anti-cancer
therapies. High MasR expression in CRC metastases, but
not in the liver, suggests that infusion of ANG-(1-7) may
also inhibit growth of CRC metastases. The data pre-
sented here indicates that the tumor RAS may be differ-
entially regulated from the adjacent liver RAS. This
independence may allow treatments to negatively target
the tumor RAS, while allowing the liver to function and
respond as normal.
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Figure 5 Immunohistochemical staining for the AT1R (A), AT2R 
(B), and MasR (C) in control and captopril treated animals at day 
16 and day 21. AT1R localised to cells within the stromal intrusions of 
CRC metastases with light staining also observed in tumor cells at the 
periphery (A). There appeared to be a greater number of AT1R-positive 
cells in and around CRC metastases in control compared to the capto-
pril treated animals, supporting mRNA analysis for this receptor (Figure 
2). AT2R protein localized to tumor cells only with no staining evident 
in the liver (B). MasR staining was found within and around the necrotic 
centre of CRC metastases and a greater number of MasR staining was 
observed in control groups as compared to the captopril treated 
groups (similar to the mRNA data presented in Figure 2). As with the 
AT2R, MasR staining was only evident in tumor cells.
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